Given that DCK affects the metabolism of gemcitabine, a first-line nucleoside analog drug used to treat PC, much of the existing literature focuses on its role in gemcitabine metabolism, though its direct impact on PC remains underexplored. This evidence concerns the gene DCK and pachyonychia congenita.